1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. HERPES SIMPLEX VIRUS TREATMENT MARKET BY TREATMENT
5.1. Introduction
5.2. Herpes Simplex Virus-1
5.2.1. Market Trends and Opportunities
5.2.2. Growth Prospects
5.2.3. Geographic Lucrativeness
5.3. Herpes Simplex Virus-2
5.3.1. Market Trends and Opportunities
5.3.2. Growth Prospects
5.3.3. Geographic Lucrativeness
6. HERPES SIMPLEX VIRUS TREATMENT MARKET BY DRUG
6.1. Introduction
6.2. Acyclovir
6.2.1. Market Trends and Opportunities
6.2.2. Growth Prospects
6.2.3. Geographic Lucrativeness
6.3. Valacyclovir
6.3.1. Market Trends and Opportunities
6.3.2. Growth Prospects
6.3.3. Geographic Lucrativeness
6.4. Famciclovir
6.4.1. Market Trends and Opportunities
6.4.2. Growth Prospects
6.4.3. Geographic Lucrativeness
6.5. Others
6.5.1. Market Trends and Opportunities
6.5.2. Growth Prospects
6.5.3. Geographic Lucrativeness
7. HERPES SIMPLEX VIRUS TREATMENT MARKET BY END-USER
7.1. Introduction
7.2. Hospital Pharmacy
7.2.1. Market Trends and Opportunities
7.2.2. Growth Prospects
7.2.3 Geographic Lucrativeness
7.3. Retail Pharmacy
7.3.1. Market Trends and Opportunities
7.3.2. Growth Prospects
7.3.3. Geographic Lucrativeness
7.4. Online Pharmacy
7.4.1. Market Trends and Opportunities
7.4.2. Growth Prospects
7.4.3. Geographic Lucrativeness
8. HERPES SIMPLEX VIRUS TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Treatment
8.2.2. By Drugs
8.2.3. By End-User
8.2.4. By Country
8.4.1.1. United States
8.4.1.2. Canada
8.4.1.3. Mexico
8.3. South America
8.3.1. By Treatment
8.3.2. By Drugs
8.3.3. By End-User
8.3.4. By Country
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. The Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Israel
8.5.4. Others
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
10. COMPANY PROFILES
10.1. A-Vax Technology
10.2. BioNTech
10.3. Mayo Clinic
10.4. Maruho
10.5. The Native Antigen Company
10.6. Cedars-Sinai
10.7. Kirk Eye Center
10.8. Rational Vaccines
10.9. Zovirax